On Aug. 31, 2021, RELIEF THERAPEUTICS reported that the parent company of its U.S. collaboration partner, NRx Pharmaceuticals announced that a new analysis showed that patients treated with ZYESAMI demonstrated improvement in blood oxygen, indicative of improved lung function, within a day of starting treatment.